

Reference number
1756-H

SPECIALTY QUANTITY LIMIT PROGRAM

TARCEVA (erlotinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-Recommended dosing
Tarceva 25 mg tablets	60 per 30 days	Not applicable	Non-small cell lung cancer (NSCLC): 150 mg once daily
Tarceva 100 mg tablets	30 per 30 days	120 per 30 days	Pancreatic cancer: 100 mg once daily
Tarceva 150 mg tablets	30 per 30 days	90 per 30 days	-Up to 300 mg if cigarette smoker - Up to 450 mg if co-administered with a strong CYP3A4 inducer

* Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Tarceva [package insert]. South San Francisco, CA: Genentech USA, Inc.; October 2016.